Anti Malarial Medicine

Approx. Rs 185 / StripeGet Latest Price

Product Details:

Chloroquine is used to prevent or treat malaria caused by mosquito bites. Chloroquine belongs to a class of drugs known as antimalarials 

Approx. Rs 140 / StripeGet Latest Price

Product Details:

Artesunate injection is used to treat severe malaria. This medicine is also used together with other medicines (eg, 8-aminoquinoline medicine) to treat severe malaria caused by Plasmodium ovale or Plasmodium vivax. Artesunate belongs to a group of medicines known as antimalarials. 

Approx. Rs 156 / BoxGet Latest Price

Product Details:

The combination of artemether and lumefantrine is used to treat certain kinds of malaria infections (a serious infection that is spread by mosquitoes in certain parts of the world and can cause death) 

Approx. Rs 70 / KgGet Latest Price

Product Details:

(Quinine sulfate) is an antimalarial drug used to treat malaria, a disease caused by parasites. Parasites that cause malaria typically enter the body through the bite of a mosquito. Malaria is common in areas such as Africa, South America, and Southern Asia. 

Approx. Rs 600 / StripeGet Latest Price

Product Details:

• We are engaged in offering Lariago Chloroquine Phosphate Tablet to our clients. Our range of all products is widely appreciated by our clients. 

Approx. Rs 2,000 / BottleGet Latest Price

Product Details:

Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.
The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.
Safety controversyIn April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties.[3] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals